OSUCCC—James study suggests inhibition of SUSD2 protein improves CAR T-cell therapy effectiveness

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Tampa General Hospital and Mass General Brigham announced a strengthening of their affiliation with the development of new programs and services, including a bone marrow transplant program and CAR T therapy program, at TGH.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Clinical Roundup

Five-year study identifies long-term effects of axi-cel CAR T treatment

Axicabtagene ciloleucel, commonly known as axi-cel, is an immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.

August 09, 2024

Vol.50 No.32

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

In Brief

Christian Rolfo named director of Ohio State Division of Medical Oncology

Christian Rolfo was named director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He will start on Aug. 15.

June 21, 2024

Vol.50 No.25

OSUCCC—James study suggests inhibition of SUSD2 protein improves CAR T-cell therapy effectiveness

YOU MAY BE INTERESTED IN

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

Christian Rolfo named director of Ohio State Division of Medical Oncology

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

OSUCCC—James study suggests inhibition of SUSD2 protein improves CAR T-cell therapy effectiveness

YOU MAY BE INTERESTED IN

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

Christian Rolfo named director of Ohio State Division of Medical Oncology

Can you spare 10 minutes to complete a survey?

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence